DMPK

Leadership:

TJ Deng, Ph.D., vice president of emerging business and product development
Jeng-Pyng Shaw, Ph.D., executive director of DMPK
Song Zheng, M.S., senior group leader of DMPK

Since 2006, BioDuro has been building in vitro ADME and PK study capabilities to support internal integrated medicinal chemistry programs and to provide a platform for external clients for early drug metabolism and pharmacokinetics (DMPK) screening. More than two-thirds of the team have postgraduate degrees and 15 percent have international training and/or experience.

We have established and validated a panel of in vitro assays, and provide services for international pharmaceutical and biotechnology companies. We offer a variety of services, including:

In vitro ADME

Physicochemical properties
- Solubility
- LogD
- Chemical stability
- Plasma stability
- Plasma protein binding
In vitro drug metabolism
- Liver microsome/hepatocyte stability
- CYP phenotyping
- Metabolite ID (Phase I and II)
Permeability
- Caco-2
- PAMPA
Drug-drug interaction
- CYP inhibition assay

PK Studies

Small molecules and biologics
Various routes of administration
Crossover or noncrossover
Multiple cannulation procedures
Distribution in tissues
Metabolite identification
Bioanalytical method development, formulation development and bioanalysis
AAALAC accredited facilities